Showing 1 posts of 1 posts found.
France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …
Hot-tub therapy tested as potential treatment for peripheral artery disease
Raimond takes helm at Nuclera
Most advanced breast cancer patients treated in community settings, Phesi study finds
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Bramacare opens supported-living facility for eating disorder recovery